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nonapoptotic roles of granzymes, in ac-
cord with the prescient predictions made
by Kramer and Simon (1987) more than
twenty years ago.
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Figure 1. Granzymes: Extrinsic Activators of Cell Death and Inflammation that Mimic
Intrinsic Caspase Pathways
Granzyme B, which like the proapoptotic caspases cleaves after specific Asp residues, is transferred from
a cytotoxic lymphocyte into the cytoplasm of a target or antigen-presenting cell to impose death in
response to virus infection or malignant transformation. Granzyme B (red dots) mediates this process in
a perforin-dependent manner, as perforin (purple dots) provides access to its cytoplasmic substrates.
The principal function of other (non-Asp-ase) granzymes (green and blue dots) within the target cell may
be to mimic the proinflammatory caspases that are critical for inflammasome formation and release of cy-
tokines such as IL-1b, IL-6, and TNF. It is presumed that this function of granzymes is also perforin depen-
dent but this remains to be formally demonstrated. Other intrinsic cell-death and proinflammatory pathways
can be activated by stimuli other than the granzymes, for example inflammatory stimuli operating through
Toll-like receptors (TLR), cell death through ligation of death receptors (DR), or mitochondrial perturbation.
In some situations, it might also be possible for granzymes other than B to activate target cell death, but far
less efficiently than granzyme B. Other granzyme functions (cell detachment, chemotaxis, lymphocyte
migration through the extracellular matrix) occur in the extracellular space and are independent of perforin.
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Self-reactive B cells are eliminated during development by antibody-affinity selection and receptor-editing
mechanisms. Work by Isnardi et al. (2008) in this issue of Immunity suggests that removal of autoreactivity
from the immature B cell pool also requires innate immunity pathways.The random nature of antibody diversifica-
tion processes guarantees that a large
number of newly generated antibodies
will recognize self-antigens. These poten-
tially harmful antibodies with self-specific-
ities are eliminated in large numbers at var-
ious steps of B cell development so that
the mature B cell repertoire of a healthyindividual is largely devoid of self-reactive
antibodies. Knowledge of this process has
greatly advanced ever since the Nussenz-
weig group developed a combination of
single-cell polymerase chain reaction
(PCR) and antibody-cloning techniques
to investigate single B cell specificities in
humans (Wardemann and Nussenzweig,Immunity 29, N2007). This technique is now utilized by
Isnardi et al. to characterize alterations in
the naive B cell repertoire of patients with
deficiencies in innate immune pathways
(Isnardi et al., 2008).
The analysis of B cells from healthy
individuals detects several checkpoints
against autoreactive B cells in boneovember 14, 2008 ª2008 Elsevier Inc. 667
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PreviewsFigure 1. Alterations in BothCentral andPeripheral BCell ToleranceCheckpoints in Humans
with Deficiencies in Innate Immunity
Healthy controls generate highly autoreactive repertoires in the early immature stage. A central-tolerance
checkpoint removes a large proportion of autoreactive B cells in the bone marrow, primarily through
receptor editing. Immature B cells exit from the bone marrow as new emigrant B cells, normally with
a low degree (7%) of autoreactivity. A second tolerance checkpoint occurs during B cell maturation,
although its molecular mechanism is largely unknown and might depend on BAFF or T cell help. Work
by Isnardi et al. (2008) now shows that deficiencies in IRAK-4 and MyD88 in humans result in alterations
of the central- and peripheral-tolerance checkpoints and a defect in B cell receptor editing. In contrast,
UNC93B mutations in humans change the peripheral-tolerance checkpoint, but not the central-tolerance
checkpoint.marrow and peripheral blood of healthy
humans (Wardemann and Nussenzweig,
2007). Three quarters of the newly formed
B cells are estimated to be self-reactive,
and a large proportion of those autoanti-
bodies recognize multiple specificities.
The transition from early immature to im-
mature B cells in the bone marrow is
considered to be a major checkpoint that
eliminates a large part of the originally
self-reactive antibodies (Figure 1). The
most likely molecular event underlying this
checkpoint of B cell central tolerance is re-
ceptor editing, a mechanism in which ran-
dom Ig light-chain replacement silences
self-reactive antibodies. Once immature B
cells are released from the bone marrow,
they are detected in the periphery as new
emigrant B cells (CD10+IgM+CD27) that
still harbor a substantial number of self-
reactive clones (approximately 7%). A sec-
ond tolerance checkpoint occurs in their
transition into the mature naive B cell
(CD10IgM+CD27) compartment. At this
point, less than 5% of the peripheral naive
compartment consists of autoreactive B
cells. Overall, failures in any of these two
major B cell tolerance checkpoints would
lead to higher numbersof mature autoreac-
tive B cells and would predispose to the
development of autoimmunity. This hy-
pothesis has been confirmed by the analy-
sis of B cells from patients with autoim-668 Immunity 29, November 14, 2008 ª2008mune disease in which autoantibodies
have a prominent role: The naive mature
B cell compartments of both systemic lu-
pus erythematosus (SLE) and rheumatoid
arthritis patients contain a large number of
autoreactive B cells irrespective of their
disease treatment course.
Antibody-affinity selection seems to un-
derlie the removal of autoreactive B cells
from the repertoire in the first tolerance
checkpoint. First, antibodies with very
high affinity for self are removed by clonal
deletion in early development. Next,
antigen-receptor editing by light-chain
replacement occurs in many of the re-
maining self-reactive B cells and depends
largely on the strength of B cell receptor
(BCR) signaling. This idea has been cited
as a means of explaining the fact that
X-linked agammaglobulinemia (XLA) pa-
tients with defective BCR signals exhibit
signs of extensive secondary Ig light-
chain recombination and are frequently
self-reactive (Ng et al., 2004). Following
this line of thinking, any other alteration
in the strength of the BCR would be
expected to greatly modify B cell cen-
tral-tolerance outcomes. In fact, lower
responsiveness to antigen-receptor stim-
ulation is now invoked as a possible
explanation for the augmented autoreac-
tivity in systemic autoimmune diseases
like SLE (Grimaldi et al., 2007).Elsevier Inc.The second checkpoint for self-toler-
ance occurring in the periphery at the B
cell maturation stage is less mechanisti-
cally defined and could be affected by sig-
nals other than the BCR. For example,
changes in sensitivity to the B cell-activat-
ing factor BAFF oroverall amounts of BAFF
in the periphery have been proposed to
affect this selection process. Additionally,
analysis of patients with defects in CD40L
or major histocompatibility complex class
II (MHC-II) supports a tolerogenic effect
of T cell help in this peripheral-tolerance
checkpoint: CD40L- and MHC-II-deficient
patients express a higher proportion of au-
toreactive antibodies in their naive mature
B cell compartments, whereas their central
tolerance seems unaltered (Herve et al.,
2007). How selection of the naive B cell
compartment is regulated by T cell help is
at the moment unclear. It nevertheless
highlights the fact that B cell tolerance
might be regulated by additional pathways
yet untested.
Current work by Isnardi et al. expands
our view of genetic factors that alter the
human B cell repertoire by analyzing the
effect of deficiencies in innate immune
pathways. Specifically, B cells from pa-
tients with complete defects in the genes
encoding interleukin-1 receptor-associ-
ated kinase 4 (IRAK-4), myeloid differenti-
ation factor 88 (MyD88), and UNC-93B
were evaluated for autoreactive specific-
ities (Isnardi et al., 2008). In humans, mu-
tations in the genes encoding MyD88 and
IRAK-4 predispose to recurrent bacterial
infections, but they appear to be less crit-
ical in the prevention of viral infections. In
contrast, mutations in the UNC93B gene
predispose to herpes simplex encephali-
tis (Zhang et al., 2007). These defects
are generally consistent with the role
that these three molecules play in trans-
mitting signals initiated by interleukin-1
(IL-1) receptors and Toll-like receptors
(TLRs), all important pathways in the fight
against pathogens. IRAK-4 and MyD88
associate and mediate signaling of all
known TLRs except TLR3. Both molecules
also associate with the IL-1 family of re-
ceptors. Meanwhile, UNC93B’s function
is to deliver TLRs from the endoplasmic re-
ticulum to endolysosomes and is essential
for signaling of TLR3, TLR7, and TLR9, all
three TLRs with intracellular localization
(Kim et al., 2008; Tabeta et al., 2006).
The analysis of B cells from patients
with defects in the IRAK-4, MyD88, and
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et al. (2008) provides some intriguing
results that support an expanded role of
innate receptors in shaping the antibody
repertoire at early stages of B cell develop-
ment. When tested for B cell specificities
by the single B cell antibody-cloning tech-
nique, IRAK-4-deficient patients showed
the most unambiguous differences in B
cell repertoire compared to healthy con-
trols: Half of the new emigrant immature
B cells in IRAK-4-deficient individuals
were still self-reactive against multiple
antigens, and most of them were still au-
toreactive at the mature naive stage, com-
pared to less than 5% autoreactive B cells
present in healthy controls. Moreover,
a large proportion of those autoantibodies
present in IRAK-4-deficient patients were
reactive against double-stranded DNA or
other nuclear antigens. The single MyD88-
deficient patient analyzed showed a simi-
lar trend as in the IRAK-4 case, albeit of
lower magnitude. On the other hand,
mutations in the UNC93B gene did not
change the proportion of autoreactive im-
mature B cells but did slightly increase the
number of autoreactive B cells in the pe-
riphery (Isnardi et al., 2008). These results
imply that IRAK-4 and MyD88 are essen-
tial for the establishment of both the cen-
tral and peripheral checkpoints for B cell
tolerance, whereas UNC93B would only
be strictly required for the peripheral-toler-
ance checkpoint. These divergent results
can be interpreted in various ways. They
could mean that IRAK-4 and MyD88 defi-
ciencies affect early B cell populations
through pathways that do not depend on
intracellular TLRs. However, human B
cells seemed to be mostly devoid of the
common TLRs with extracellular expres-
sion, and they also lack receptors for
IL-1. Another possibility is that UNC93B,
which has low expression in human B
cells, could be somewhat redundant in
its function. Consistent with this view,
UNC93B deficiency in humans is not
completely penetrant (Zhang et al.,
2007). Further analysis of more of these
rare patients with innate immunity defi-ciencies and, more specifically, those
with mutations on the TLR receptors
themselves will be helpful in clarifying
these questions.
In terms of the molecular events under-
lying IRAK-4- and MyD88-deficient pa-
tients’ defect in central B cell tolerance,
sequence analysis of autoantibodies
present in these patients showed that
they lack most signs of receptor editing
that are observed in autoreactive anti-
bodies of healthy individuals. This is in
clear contrast with what was observed
in cases of hyporesponsive BCR, such
as in XLA patients, in which extensive
recombination events were observed in
self-reactive antibodies. Thus, it can be
argued that the main effect of the IRAK-4
and MyD88 deficiencies in B cell toler-
ance could be unrelated to the antibody-
affinity selection process.
The augmented autoreactivity of the
naive B cell repertoire in IRAK and
MyD88 deficiencies in humans seems
counterintuitive, considering the current
understanding of the role of TLRs in auto-
immune responses, which is primarily
based on in vitro and mouse work. The
general view is that TLRs play a key role
in the expansion of autoreactive B cells
because certain TLRs can synergize with
nucleic-acid-binding BCRs to stimulate
B cell proliferation and differentiation
(Marshak-Rothstein and Rifkin, 2007).
Two intracellularly located TLRs have
been most prominently implicated in pro-
moting autoreactivity: the single-stranded
RNA-binding TLR7 and the CpG DNA-
binding TLR9. Both TLR7 and TLR9
require IRAK-4, MyD88, and UNC93B for
the induction of proper cell activation in
humans and in mice. Our lesson from
the analysis of human B cells is that
TLRs may not just regulate B cell activa-
tion in the periphery, but they may also
shape the naive B cell repertoire. Of
course, this effect of TLRs on immature
B cell populations could be extrinsic to
the B cells and just a consequence of an
altered environment in the bone marrow.
This possibility cannot be easily assessedImmunity 29, Nin the human system, but it could be easily
tested in MyD88- and IRAK-4-deficient
mice.
Would the IRAK-4 and MyD88 defi-
ciencies predispose to autoimmune
disease, considering the large number of
autoreactive B cells in the naive compart-
ment? The answer seems to be no, be-
cause no autoantibodies were detected
in the serum of these patients. Thus,
even though autoreactive B cells per-
sisted in the repertoire, these cells were
not activated further in the periphery
because of a lack of TLR activation sig-
nals. TLR inhibitors are now proposed as
therapeutic treatment of autoimmune
disease. This analysis of IRAK-4- and
MyD88-deficient patients suggests that
this kind of treatment not only will inhibit
B cell activation in the periphery, but that
it can also potentially alter the antibody
repertoire as a whole.
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